Aurobindo Pharma jumps on getting EIR for Andhra Pradesh manufacturing facility

20 Dec 2023 Evaluate

Aurobindo Pharma is currently trading at Rs. 1051.85, up by 19.15 points or 1.85 % from its previous closing of Rs. 1032.70 on the BSE.

The scrip opened at Rs. 1037.10 and has touched a high and low of Rs. 1081.45 and Rs. 1034.70 respectively. So far 157591 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1081.45 on 20-Dec-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023.

Last one week high and low of the scrip stood at Rs. 1081.45 and Rs. 1009.55 respectively. The current market cap of the company is Rs. 61678.83 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 40.74% and 7.42% respectively.

The United States Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) to Aurobindo Pharma’s wholly owned subsidiary -- APL Healthcare’s Unit IV, a Formulation manufacturing facility situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh. The said facility has been classified as Voluntary Action Indicated (VAI). 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1245.00 4.30 (0.35%)
23-Dec-2024 10:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1815.00
Dr. Reddys Lab 1351.40
Cipla 1476.15
Lupin 2172.00
Zydus Lifesciences 974.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.